The World Congress on Controversies in Neurology

Home
Welcome Note
Committees
Scientific Program
Timetable
Poster Presentations
General Information
Sponsors
Accompanying Persons’ Program
Past & Future CONy Congresses

 
The World Congress on Controversies in Neurology
The World Congress on Controversies in Neurology
 Sponsors   Registration   Accommodation   Contact 

 
Scientific Program
 
 

Thursday, September 6, 2007

16:00-18:00 Plenary Session

16:00-16:30

Opening remarks

  A.D. Korczyn, Israel

V. Hachinski, Canada

K. Einhaeupl, Germany

   

16:30-17:00

The role of controversies in the growth of knowledge

 

M. Dascal, Israel

17:00-17:30

Cognitive agnosia: An underdiagnosed cause of controversies

 

V. Hachinski, Canada

17:30-18:00

Accelerating drug discovery by venture philanthropy

 

H. Fillit, USA

    

18:00

Welcome Reception


Friday, September 7, 2007
Hall A

Session 1    

08:30-10:00

Multiple Sclerosis (MS)
Sponsored by an unrestricted grant from Biogen Idec

 

Capsule: Many people believe that MS is a syndrome rather than a single nosologic entity. The role of auto-immune processes is also still problematic and the respective role of T cells and B cells is debated. This has important implications for therapy.

 
Chairpersons: G. Comi, Italy; Z. Stelmasiak, Poland
     

08:30-09:30

Debate: MS is a single nosologic entity due to an auto-immune mechanism

 

Yes: H.P. Hartung, Germany

 

No: I. Steiner, Israel

    

09:30-10:00

Alemtuzumab (Campath) in early MS

 

V. Brinar, Croatia

   

10:00-10:30

Coffee Break

    
Session 2  

10:30-12:30

Anti-Interferon Antibodies
Sponsored by an unrestricted grant from TEVA & Sanofi Aventis

Capsule: Treatment with interferons (IFNs) provokes in some cases the production of naturalizing antibodies (NABs). Their clinical significance is still unclear and their management is still under debate.

  Chairpersons: V. Brinar, Croatia; A. Miller, Israel
   

10:30-11:30

Weak points in MS diagnosis

 

G. Giovannoni, UK

11:00-11:30

Role of Biomarkers in diagnosis and treatment

 

K. Selmaj, Poland

 

 

11:30-12:30

Debate: Does the presence of NABs against IFNs necessitate a switch to another class of therapy

 

Yes: P.S. Sorensen, Denmark 
 

 No: J. Oger, Canada

 

12:30-13:30

Lunch Break

  

  

Session 3  

13:30-15:30

Treatment Strategies for Multiple Sclerosis
Sponsored in part by an unrestricted grant from Bayer Schering Pharma

  

Capsule: Many issues regarding when and how to start treatment and what are the future avenues are not clear!

  Chairpersons: W. Carroll, Australia; K. Rejdak, Poland
    

13:30-14:30

Debate: Clinically isolated syndromes (CIS): to treat or not to treat

 

Start early: G. Comi, Italy

 

No hurry: A. Siva, Turkey

 

 

14:30-15:30

Debate: Is stem cell therapy an imminent treatment in advanced MS?

 

Stem cell therapy in MS is a real option: G. Martino, Italy

 

Bioethical aspects of human embryonic stem cells are still an issue: M. Revel, Israel

   
15:30-16:00 Coffee  Break
   
Session 4  
16:00-17:30
Multiple sclerosis - Neuroproctection
  Sponsored in part by an unrestricted grant from Merck Serono
  Capsule: While there is no doubt that interferons and copaxone can reduce relapse rate in MS, it is still unclear if, how, and to what extent they can reduce the Accumulation of disability.
  Chairpersons: G. Comi, Italy; I. Milonas, Greece
   
 16:00-17:00 Debate: Neuroprotective effect of IFNs and copaxone in MS - myth or reality?
  Myth: C. Constantinescu, UK
  Reality: X. Montalban, Spain
   
Session 5  
17:00-18:00 Free Communications -Multiple sclerosis
  Chairpersons: P. Calabrese, Germany; M. Sakkopoulou, Greece
   
17:00-17:15
Immediate treatment with IFNB-1b after a first event suggestive of MS delays persistant neurological impairment
  X. Montalban, Spain
17:15-17:30
Use of stem cells preparations for the treatment of patients suffering from multiple sclerosis adn immunological control of treatment efficiency
  N. Mkrtchyan, Russia
17:30-17:45
Comparison of interferon beta productions and azathioprine in treatment of relapsing-remitting multiple sclerosis
  M. Janghorbani, Iran
17:45-18:00 Facial Palsy in Iranian patients with Multiple Sclerosis
  Y. IIkhchoui, Iran
 

Friday, September 7, 2007
Hall B
Session 6  

08:30-10:00

Management of Transient Ischemic Attacks (TIA’s)

 

Capsule: TIA’s are frequently undiagnosed, misdiagnosed or mistreated.

 

Chairpersons: N. Bornstein, Israel; K. Einhaeupl, Germany

   

08:30-09:30

Debate: Testing for right-to-left cardiac shunt

 

The PFO should be closed before the first cerebral event: B. Meier, Switzerland

  No: The cost is too high, the yield too low: C. Diener, Germany
   

09:30-10:00

When and how to look for CADASIL and Fabry?
 

A. Rolfs, Germany

   

10:00-10:30

Coffee Break

   
Session 7  

10:30-12:30

Interventions in Secondary Stroke Prevention

  Chairpersons:  O. Bajenaru, Romania; O. Bartko, Slovakia
   

10:30-11:30

Debate: Drug therapy for TIA

 

Immediate aspirin and dipyridamole: C. Diener, Germany 

 

Immediate clopidogrel: J. Streifler, Israel

   

11:30-12:30

Debate: Carotid stenting is better than carotid endarterectomy

 

Capsule: Stenting is an effective procedure and in time may replace surgery for most patients.

 

Yes: J. Wojczal, Poland

 

No: N. Bornstein, Israel

 

 

12:30-13:30

Lunch Break

 

 

Session 8  

13:30-15:30

Management of Acute Stroke

 

Capsule: Patients with acute stroke are frequently admitted to general medical or neurological wards, where important factors are not attended to, leading to clinical deterioration

  Chairpersons: V. Hachinksi, Canada; J. Streifler, Israel
   
13:30-14:00 Management of hyperglycemia and hypertension in acute stroke
G.M. Boysen, Denmark
14:00-14:30 tPA beyond time and age limits
E. Stolz, Germany
14:30-15:00 Intra-arterial thrombolysis
A. Ciccone, Italy

15:00-15:30

Discussion

   

15:30-16:00

Coffee Break

 

 

Session 9  

16:00-18:00

Pathogenesis of Parkinson's Disease (PD)
Sponsored in part by unrestricted grants from SCHWARZ PHARMA and ORION

 

Capsule: Despite much research, the pathogenesis of PD is still contested. Is there one cause that can be thought of as initiating the cascade?

 

Chairpersons: V. Kostic, Serbia; M. Ghabaee, Iran

   

16:00-16:30

PD is a mitochondrial dysfunction disease

 

M. Youdin, Israel

16:30-17:00

PD is due to protein dysfunction

 

W. Olanow, USA

17:00-17:30

Is PD a ferrinopathy?

 

D. Berg, Germany

17:30-18:00

Olfactory dysfunction in early PD suggests that the disease is caused by a toxin

 

H. Reichmann, Germany

   
Session 10  
18:00-18:30 Free Communications - Various Topics 
  Chairpersons: K. Bayulkem, Turkey; J. Wojczal, Poland 
   
18:00-18:10 Visual loss in idiopathic intracranial hypertension despite normal intracranial pressure
  H.E. Killer, Switzerland
18:10-18:20  Aspirin resistance correction in the aged patients after first ever ischemic stroke
  V.G. Karepov, Israel
18:20-18:30
   
  

Z. Rozhkova, Ukraine

 

Friday, September 7, 2007
Hall C

Session 11  
08:30–10:00
Autoimmune Dementia
 
Capsule: In addition to the common causes of dementia, some patients are thought to have an underlying autoimmune mechanism. When should these be considered and how should they be treated?
 
Chairpersons: A. Kertesz, Canada; T.A. Treves, Israel
   
08:30-08:50
 
A. Chaudhuri, UK 
08:50-09:10
 
A. Vincent, UK
09:10-9:30
 
 J. Chapman, Israel
09:30-09:50
  P. Calabrese, Germany
09:50-10:00
Discussion
 
 
Session 12  
10:00-10:30
Coffee Break
 
 
10:30-11:30
A Cure for Alzheimer's Disease (AD)
 
Capsule: Because beta-amyloid is a hallmark of AD, attempts are being made to eliminate this protein. One of the new methods to achieve this is through anti-amyloid immunization, while a competitive method is by inhibition of APP-cleaving enzymes.
  Chairpersons: J. Callaway, USA; M. Youdim; Israel 
   
 
Debate: Immunization will cure AD
 
Yes: R. Nitsch, Switzerland
 
No: E. Giacobini, Switzerland
 
 
Session 13  
11:30-12:30
Treatment of Cognitive Impairment
 
Capsule: Cholinesterase inhibitors (ChEI's) and memantine are the only approved drugs for the treatment of Alzheimer’s disease (AD), but there is debate on their efficacy, both in MCI and (even more) in advanced AD.
 
Chairpersons: L. Battistin, Italy; D. Muresanu, Romania
   
11:30-12:00
 
M. Youdim, Israel
12:00-12:30
 
H. Fillit, USA
 
 
12:30-13:30
Lunch Break
 
 
Session 14  
13:30-15:30
Non-Alzheimer Dementias
 
Chairpersons: M. Davidson, Israel; P.J. Visser, The Netherlands 
   
13:30-14:30
Debate: Vascular cognitive impairment is a misleading concept
 
Capsule: Dementia or milder forms of cognitive decline can occure following obvious strokes or in conjunction with vascular risk factors. Recently the term vascular cognitive impairment has been suggested to encompass vascular dementia, Biswanger’s disease and multi-infarct dementia. However, this term has not been unchallenged.
 
Yes: A. Kertesz, Canada
 
No: V. Hachinski, Canada
 
 
14:30-15:30
Debate: Dementia with Lewy bodies and dementia of Parkinson’s disease are the same disorder
 
Yes: L. Battistin, Italy
 
No: G. Ransmayr, Austria
 
 
15:30–16:00 
Coffee Break
 
 
Session 15  
16:00-18:00
Mild Cognitive Impairment (MCI)
 
Capsule: Dementia typically develops insidiously. An intermediate stage between normai aging and dementia termed mild cognitive impairment (MCI) is still not well understood nor generally accepted and there is no agreement on how it should be treated.
 
Chairpersons: Y. Lerman, Israel; P. Werner, Israel 
   
16:00-17:00
Debate: Is MCI a useful concept?
 
Yes: S. Gauthier, Canada
 
No: J.C. Morris, USA
   
17:00-18:00
Debate: Treatment of MCI is available and should be given
 
Yes: L. Spiru, Romania
 
No: P.J. Visser, The Netherlands
 
 
Session 16  
18:00-18:30
Free Communications - Various Topics
  Chairpersons: B. Popescu, Romania; N. Razon, Israel 
   
18:00-18:10 Immunotherapy of neurological paraneoplastic syndromes - disappointing or effective?
  S. Michalak, Poland 

18:10-18:20

Determinants of functional loss in patients with glioma in eloquent areas: a pre and postoperative fMRI study
  V. Gonzalez-Felipe, Germany
18:20-18:30 
Activated Factor VII (Novoseven) for Acute Intracerebral Hemorrhage: Experience of 15 Cases From a Single Centre
  S. Kumar, India  
 

Saturday, September 8, 2007
Hall A
 
Session 17  

08:30-10:00

Psychogenic Neurological Disorders

 

Capsule: Clinicians are still facing frequent difficulties in differentiating "organic" from "functional" disorders.

  Chairpersons: T. Lempert, Germany; I. Steiner, Israel
   

08:30-08:50

Is psychogenic dystonia a valid diagnosis?

 

K. Black, USA

08:50-9:10

Is Regional Sympathetic Dystrophy (RSD) - Dystonia an organic disease? 

 

M. Hallet, USA

09:10-09:30
 
C.Elger, Germany
9:30-9:50 Vertigo as a psychogenic disorder
   M. Strupp, Germany
09:50-10:00 Discussion
   

10:00-10:30

Coffee Break

 

 

Session 18  

12:30-14:30

Satellite Lunch Symposium
Sponsored by Elan
Can Neurodegenerative Diseases be Slowed or Reversed?
Elan's Look into the Future

 

 

12:30-12:40 Opening remarks
  A.D. Korczyn, Israel
12:40-13:20 Natalizumab and Beyond:  Elan’s Look into the future of the science of neurodegeneration
  T. Yednock, USA
13:20-13:50 Can Alzheimer’s disease progression be Slowed or reversed?
  D. Schenk, USA
13:50-14:15 Are anti-amyloid therapies the answer?
  R. Jones, USA
14:15-14:30 Q & A; Closing remarks
  A.D. Korczyn, Israel
   
Session 19  

16:30-18:00

Free Communications - Stroke

 
Chairperson: V. Karepov, Israel
   
16:30-16:45

Protection from brain damage and bacterial infection in murine stroke by the novel caspase-inhibitor Q-VD-OPH

 

J. Braun, Germany

16:45-17:00

Carotid endarterectomy vs carotid stenting - Critical overview and leader expert's opionion

 

D. Bartko, Slovakia

17:00-17:15  Is mannitol useful in intracerebral hemorrhage?
   U. Misra, India

17:15-17:30

Combined Therapy of tPA and UK for actute ischemic stroke

 

W. Zhang , China

17:30-17:45

The incidence and determinations of Sleep Apnea Syndrome in patients with spinal cord injury and stroke

 

T. Van Bezeij, The Netherlands

17:45-18:00 Hemidystonia in stroke

 

A. Subbiah, India

 

Saturday, September 8, 2007
Hall B

Session 20  

08:30-10:00

Autoimmune Disorders
Sponsored in part by an unrestricted grant from Talecris

 

Capsule: The pathogenesis of several autoimmune diseases is still unclear. What is the role of antibodies and which treatements are available?

  Chairpersons: N. Mironov, Russia; Z. Petelin Gadze, Croatia 
   

08:30-09:00

The autoimmune spectrum of myasthenia

 

A. Vincent, UK

   

09:00-10:00

Debate: Treatment of chronic inflammatory demyelinating neuropathy (CIDP)

 
Treatment with IVIG: H.P. Hartung, Germany
 
Other Treatments: J. Chapman, Israel
   

10:00-10:30

Coffee Break

   
Session 21  

14:30-16:00 

Epilepsy
Capsule: Patients with epilepsy who are unresponsive to drugs should be considered for surgery and the identificatin of suitable cases usually involves expensive videotaping and seizure monitoring.
  Chairpersons: S. Benbadis, USA; D. Schmidt, Germany

14:30-15:15

Debate: Is video EEG monitoring always necessary before performing epilepsy surgery?

 
Yes: H. Stefan, Germany

  

No: M.R. Sperling, USA

 

 

15:15-16:00

Debate: Deep Brain Stimulation (DBS) is ready for clinical use in refractory epilepsy

 

Yes: P. Boon, Belgium

 

No: C. Elger, Germany

 

 

16:00-16:30 

 Coffee Break

 

 

Session 22  
16:30-17:30 Resistant Epilepsy 
Capsule: About 20% of epilepsy patients do not respond adequately to drugs. What is the treatment of choice?

 

Chairpersons: P. Boon, Belgium; C. Elger, Germany
   

 

Debate: What to do when two drugs fail?

 

Try a third drug: D. Schmidt, Germany

 

Vagal Nerve Stimulation (in suitable patients): K. Vonck, Belgium

 

Ablative surgery: S. Benbadis, USA

     

Session 23 

 

17:30-18:30

Free Communications- Various Topics

 

Chairpersons: J.T. Apter, USA; K. Vonck, Belgium

    

17:30-17:45

Epilepsies with occipital epileptiform discharges-electronical characteristics

 

M. Mazurkiewicz-Beldzinska, Poland

17:45-18:00

What role does biofeedback therapy have in the treatment of migraine

 

M. Rashidi, UK

18:00-18:15

Lorazepam in treatment of convulsive status epilepticus in children: A randomized controlled trial 

  

P. Gupta, India

18:15-18:30 Discussion 
 

Saturday, September 8, 2007
Hall C
 
Session 24  

08:30-10:00

Parkinsons Disease (PD): Early Treatment
Sponsored in part by an unrestricted grant from Merck Serono

 

Capsule: Motor complications are disabling complications of PD therapy. How can they be avoided?

  Chairpersons: O. Bajenaru, Romania; A. Gordin, Finland
     

08:30-09:00

MAOB-inhibitors should be the first line drug in early PD

 

A. Ludolph, Germany

09:00-09:30

Dopamine Agonists are the treatment of choice in early PD

 

M. Guttman, Canada

09:30-10:00

New Treatment Advances in early PD

 

F. Stocchi, Italy

 
   
10:00-10:30 Coffee Break
   
Session 25  
10:30-12:30
 
Neuroprotection and Neuroplasticity
Sponsored by SSNN
Capsule: One of the important issues in stroke therapy is the protection of neurons in the penumbra region. Several Studies have failed to identify treatments which could help. Why and how to overcome these difficulties? 
  Chairpersons: A. Ludolph, Germany; L. Vecsei, Hungary
   
10:30-10:50 Blood-brain barrier and neuroprotection
  H.S Shanker, Sweden
10:50-11:10 Vascular Protection in Stroke
  O. Bajenaru, Romania
11:10-11:30 Neuroprotection in acute ischemic stroke - Is there still hope?
  N. Bornstein, Israel
11:30-11:50 Prophylaxis in neuroprotection. An innovative approach
  L. Csiba, Hungary
11:50-12:10 Neuroprotection and neuroplasticity - a dualistic vision of a continuous process
 
D. Muresanu, Romania
12:10-12:30 Discussion
 
 
Session 26  
14:30-16:00 Treatment of Advanced PD
  Capsule: How can we best control the motor complications in advanced PD?  
  Chairpersons: M. Guttman, Canada;  M. Hilz, Germany 
   
14:30-14:50 Intraduodenal levodopa
  D. Truong, USA
14:50-15:10 Apomorphine infusions in complicated PD
  D. Dressler, Germany
15:10-15:30 Deep Brain Stimulation (DBS)
  A. Kupsch, Germany
15:30-15:50 Spheramine-cell therapy
  E. Reissig, Germany
15:50-16:00 Discussion
   
16:00-16:30 Coffee Break
   
Session 27  
16:30-17:30 Non-Motor Aspects of PD
Capsule: Non dopaminergic symptoms may be more relevant than DA-responsive motor symptoms in PD
  Chairpersons: R. Denglar, Germany; R. Rangel Guerra, Mexico 
    
16:30-16:50 Is dementia inevitable in PD?
  I. Litvan, USA
16:50-17:10 Daytime somnolence in PD - How to avoid and how to treat?
   K.R. Chaudhuri, UK   
17:10-17:30 Treatment for PD psychosis: Which drug is most useful in clinical practice? 
   J.M. Rabey, Israel  
   
Session 28  
17:30-18:30 Parkinsonian Syndromes
  Capsule: Movement disorders with Parkinsonian features have been diagnosed using different methods, using different criteria, but the basic question remains of the nosologic entities underlying these neurodegenerative diseases.
  Chairpersons: C. Falup, Romania; J.M. Rabey, Israel 
     
  Debate: Are PSP and CBGD the same disease?
  For: A. Kertesz, Canada 
  Against: I. Litvan, USA
 

Sunday, September 9, 2007
Hall A
 
Session 29  

08:30-10:00

Dystonia
Sponsored in part by an unrestricted grant fromMerz
  Chairpersons: A. Kurdi, Jordan; T.A. Treves, Israel
     
 

Debate: Dystonia - disorder of motor programming or motor execution? 

  Capsule: Dystonia is traditionally seen as an involuntary movement, leading to treatment strategies using botulinum toxin (BTX). Viewed differently, dystonia is an “unconscious“ rather than “involuntary“ movement, caused by defective “motor routines“ in the motor program. This concept suggests that BTX, when used, should be directed into the muscles causing dystonic movement and also into their antagonists. The possible feedback can affect central mechanisms and might induce long-lasting remission.
   
 
P. Kanovsky, Czech Republic
 
R. Rosales, Philippines
   

10:00-10:30

Coffee Break

 

 

Session 30  
10:30-12:00
Restless Legs Syndrome
Sponsored in part by an unrestriced grant from Schwarz Pharma

Capsule: RLS may be the most common movement disorder, but it is still underdiagnosed and there is no consensus on its treatment.

  Chairpersons: R. Horowski, Germany; A. Kupsch, Germany 
     
10:30-11:30

Debate: Are PLMS and RLS the same disorder?

 

Yes: D. Garcia-Borreguero, Spain

 

No: M. Zucconi, Italy

   
11:30-12:00

Which treatment best avoids augmentation?

  W. Paulus, Germany


Sunday, September 9, 2007
Hall B
 
Session 31  

08:30-10:00

Treatment of Migraine: Beyond Triptans

 

Capsule: Therapy of chronic headache is frequently unsatisfactory and newer methods for symptomatic therapy are needed. Botulinum toxin injections are such methods, which have still not received wide acceptance.
  Chairpersons: Y. Frank, USA; A. Siva, Turkey
   
 

Debate: Botulinum toxin in the treatment of headache

 

Proposition: Botulinum toxin is effective for headache
S. Evers, Germany
 
Opposition: Botulinum toxin should be used cautiously
U. Reuter, Germany

 

 

10:00-10:30

Coffee Break

 

 

Session 32  
10:30-11:10
Free Communications - Multiple Sclerosis
  Chairpersons: N. Mkrtchyan, Russia; J.A. Moreira, USA 
   
10:30-10:40
Structural and functional correction of spine and spinal cord disorders for patients affected by multiple sclerosis
  A. Sukhanov, Russia
10:40-10:50 Acquired attitude, interpersonal frictions and development of multiple sclerosis
  P. Vassiliu, Greece
10:50-11:00
Treatment outcome in multiple sclerosis patients after high-dose chemotherapy (HDCT)+autologous stem cell transplantation (ASCT): Follow up results of prospective multicenter study
  A.A. Novik, Russia
11:00-11:10
 
Influence of interferon-beta switching on neutralizing antibody titers: The Austrian Switch Study (ASS)
  F. Deisenhammer, Austria
   
Session 33  
11:10-12:00 Free Communications - Various Topics
  Chairpersons: P. Kanovsky, Czech Republic; S. Schreiber, Israel
    
11:10-11:20  A dramatic effect of nandrolone decanoate in cerebral palsy
  A. Al Mosawi, Iraq
11:20-11:30
Long-term use of  levetiracetam to treat tics in children and adolescents with Tourette  syndrome
  Y. Awaad, USA
11:30-11:40
Can patterns of clinical presentation in acute spinal pathology predict diagnosis and treatment in a spine surgical unit?
  T. Thangarajah, UK
11:40-11:50 Neuroleptic Malignant Syndrome
  J. Mohtashami, Iran
11:50-12:00 Implementing Transcranial Doppler as confirmatory test in brain death criteria
  B. Sheikh, Saudi Arabia
   
Session 34  
12:00-14:00
Optimization of Treatment Benefits in Patients with MS: Exploring the Betaferon Dose-Response Curve
Satellite Symposium Sponsored by Bayer Schering Pharma
  Chairperson: B. Carroll, Australia 
     
12:00-12:15 Introduction: Current management of MS
  B. Carroll, Australia 
12:15-12:45 Experience with higher doses of interferon in MS
  O. Fernandez, Spain 
12:45-13:05 Optimizing management strategies to maximize tolerability and adherence for Betaferon
  K. Baum, Germany 
13:05-13:25 The BEYOND study
  D. Goodin, USA
13:25-13:45 The potential impact of BEYOND on case management strategies
  D. Jeffery, USA
13:45-14:00 Questions and Discussion
  B. Carroll, Australia 

 
CREATED BY WEBSTUDIO   

© All Rights Reserved 2006. Comtecmed.com